Represented Eagle Pharmaceuticals in patent litigation brought by Par Pharma companies involving Eagle’s ANDA for the generic version of Par's Vasostrict® (vasopressin injection) for the treatment of hypotension/low blood pressure in patients experiencing vasodilatory shock. After a bench trial, the Court found that Eagle’s ANDA product did not infringe Par’s asserted patents. The Federal Circuit affirmed the district court’s judgment of noninfringement.
Represented Teva in patent litigation brought by Celgene involving Teva’s ANDA for the generic version of Celgene’s Pomalyst® (pomalidomide). Teva obtained favorable settlement during expert discovery after years of litigation.
Represented Teva in patent litigation brought by Janssen involving Teva’s ANDA for the generic version of Invega Sustenna® (paliperidone palmitate) for the treatment of schizophrenia and schizoaffective disorder.
Represented biosimilar drug maker in all phases of patent dance proceedings under the BPCIA and early stages of litigation.
Represented Samsung Electronics in patent litigation brought by Greenthread concerning semiconductor devices. Case settled during expert discovery.